Study to Assess Effect of HFO MDI Propellant on Mucociliary Clearance Vs. HFA MDI Propellant in Healthy Participants

Study identifier:D5985C00006

ClinicalTrials.gov identifier:NCT05755932

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Randomized, Double-blind, Two-way Crossover Study to Assess the Effect of Hydrofluoroolefin (HFO) Propellant Metered Dose Inhaler (MDI) on Mucociliary Clearance Compared with Hydrofluoroalkane (HFA) Propellant MDI in Healthy Participants

Medical condition

Mucociliary Clearance

Phase

Phase 3

Healthy volunteers

Yes

Study drug

HFO MDI, HFA MDI

Sex

All

Actual Enrollment

35

Study type

Interventional

Age

18 Years - 60 Years

Date

Study Start Date: 14 Jun 2023
Primary Completion Date: 22 Jul 2024
Study Completion Date: 22 Jul 2024

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Crossover Assignment
Masking: -
Primary Purpose: Basic Science

Verification:

Verified 01 Jul 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria